Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
Alector (ALEC) Stock Price & Analysis
399 Followers
ALEC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.66 - $9.07
Previous Close$4.42
Volume316.97K
Average Volume (3M)663.73K
Market Cap
$426.02M
Enterprise Value-$98.51M
Total Cash (Recent Filing)$562.08M
Total Debt (Recent Filing)$37.56M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 01, 2024EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding96,384,562
10 Day Avg. Volume864,621
30 Day Avg. Volume663,730
Standard Deviation0.19
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.28
Price to Sales (P/S)27.71
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.02
Enterprise Value/Gross Profit-1.01
Enterprise Value/Ebitda0.75
Forecast
1Y Price Target
$15.17Price Target Upside249.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Alector News
PremiumCompany Announcements
Alector Inc Announces Board Retirement and New Members
Bulls Say, Bears Say
Bulls Say
Clinical DataTransferrin Receptor-ABC (TfR-ABC) showed sustained strong PK/PD effects up to 2 weeks in non-human primates (NHPs), as well as potential to enable lower peripheral dose needed to enable efficacy.
Pipeline ExpansionThe choice of using GBA1 knockout mice and showing ABC transporter-based enzyme replacement therapy can rescue GCase deficiency, a key enzyme implicated in Parkinson’s disease (PD) and Lewy Body Dementia (LBD), opens exciting possibilities for pipeline expansion down the line.
TechnologyAlector is developing a proprietary versatile blood-brain barrier technology called Alector Brain Carrier (ABC) to enable drug delivery into the CNS at lower, safer efficacious doses.
Bears Say
Clinical DevelopmentBoth the platform and individual candidates are in very early stages of development, and much remains to be elucidated with respect to the clinical profile and activity of these drugs in patients.
Competitive LandscapeHistory of competitor failures in AD presents concerns.
Stock CatalystThe event is not expected to serve as a significant catalyst for the stock.
---
Ownership Overview
35.46% Insiders
27.69% Mutual Funds
35.34% Other Institutional Investors
1.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $3.66 and its highest was $9.06 in the past 12 months.
What is Alector Inc’s market cap?
Currently, no data Available
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Aug 01, 2024 which is in 29 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on May 08, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.508 by $0.128.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -$0.5.
How many shares outstanding does Alector Inc have?
Alector Inc has 96,384,560 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.508. Following the earnings report the stock price went up 0.193%.
Which hedge fund is a major shareholder of Alector Inc?
Among the largest hedge funds holding Alector Inc’s share is Deerfield Management Company, LP. It holds Alector Inc’s shares valued at 6M.
---
Alector Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.17 (249.54% Upside)
$15.17 (249.54% Upside)
Blogger Sentiment
Bullish
ALEC Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 187.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $255.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.45%
12-Months-Change
Fundamentals
Return on Equity
-66.65%
Trailing 12-Months
Asset Growth
-15.08%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
---
ALEC Company Deck
---
ALEC Earnings Call
Q4 2024
0:00 / 0:00
---
ALEC Stock 12 Month Forecast
Average Price Target
$15.17
▲(249.54% Upside)
Technical Analysis
Best Analysts Covering ALEC
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-2.10%
assigned a buy rating 4 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -2.10% per trade.
---